A simple additive staging system for newly diagnosed multiple myeloma

被引：73

作者：

Abdallah, Nadine H. ^{[1
]}

Binder, Moritz ^{[1
]}

Rajkumar, S. Vincent ^{[1
]}

Greipp, Patricia T. ^{[2
]}

Kapoor, Prashant ^{[1
]}

Dispenzieri, Angela ^{[1
]}

Gertz, Morie A. ^{[1
]}

Baughn, Linda B. ^{[2
]}

Lacy, Martha Q. ^{[1
]}

Hayman, Suzanne R. ^{[1
]}

Buadi, Francis K. ^{[1
]}

Dingli, David ^{[1
]}

Go, Ronald S. ^{[1
]}

Hwa, Yi L. ^{[1
]}

Fonder, Amie L. ^{[1
]}

Hobbs, Miriam A. ^{[1
]}

Lin, Yi ^{[1
]}

Leung, Nelson ^{[1
,3
]}

Kourelis, Taxiarchis ^{[1
]}

Warsame, Rahma ^{[1
]}

Siddiqui, Mustaqeem A. ^{[1
]}

Kyle, Robert A. ^{[1
]}

Bergsagel, P. Leif ^{[4
]}

Fonseca, Rafael ^{[4
]}

Ketterling, Rhett P. ^{[1
]}

Kumar, Shaji K. ^{[1
]}

机构：

[1] Mayo Clin, Div Hematol, Rochester, MN 55902 USA

[2] Dept Lab Med & Pathol, Rochester, MN USA

[3] Mayo Clin, Div Nephrol & Hypertens, Rochester, MN USA

[4] Mayo Clin, Div Hematol, Phoenix, AZ USA

来源：

BLOOD CANCER JOURNAL | 2022年 / 12卷 / 01期

关键词：

PROGNOSTIC-FACTOR; GENE-EXPRESSION; CHROMOSOME-13; ABNORMALITIES; DELETION;

D O I：

10.1038/s41408-022-00611-x

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Risk stratification in multiple myeloma is important for prognostication, patient selection for clinical trials, and comparison of treatment approaches. We developed and validated a staging system that incorporates additional FISH abnormalities not included in the R-ISS and reflects the additive effects of co-occurring high-risk disease features. We first evaluated the prognostic value of predefined cytogenetic and laboratory abnormalities in 2556 Mayo Clinic patients diagnosed between February 2004 and June 2019. We then used data from 1327 patients to develop a risk stratification model and validated this in 502 patients enrolled in the MMRF CoMMpass study. On multivariate analysis, high-risk IgH translocations [risk ratio (RR): 1.7], 1q gain/amplification (RR: 1.4), chromosome17 abnormalities (RR: 1.6), ISS III (RR: 1.7), and elevated LDH (RR: 1.3) were independently associated with decreased overall survival (OS). Among 1327 evaluable patients, OS was 11.0 (95% CI: 9.2-12.6), 7.0 (95% CI: 6.3-9.2), and 4.5 (95% CI: 3.7-5.2) years in patients with 0 (stage I), 1 (stage II), and >= 2 (stage III) high-risk factors, respectively. In the MMRF cohort, median OS was 7.8 (95% CI: NR-NR), 6.0 (95% CI: 5.7-NR), and 4.3 (95% CI: 2.7-NR) years in the 3 groups, respectively (P < 0.001). This 5-factor, 3-tier system is easy to implement in practice and improves upon the current R-ISS.

引用

页数：9

共 37 条

[11] International Myeloma Working Group molecular classification of multiple myeloma: spotlight review [J].

Fonseca, R. ;

Bergsagel, P. L. ;

Drach, J. ;

Shaughnessy, J. ;

Gutierrez, N. ;

Stewart, A. K. ;

Morgan, G. ;

Van Ness, B. ;

Chesi, M. ;

Minvielle, S. ;

Neri, A. ;

Barlogie, B. ;

Kuehl, W. M. ;

Liebisch, P. ;

Davies, F. ;

Chen-Kiang, S. ;

Durie, B. G. M. ;

Carrasco, R. ;

Sezer, Orhan ;

Reiman, Tony ;

Pilarski, Linda ;

Avet-Loiseau, H. .

LEUKEMIA, 2009, 23 (12) :2210-2221

[12]

Fonseca R, 2002, CANCER RES, V62, P715

[13] The t(4;14)(p16.3;q32) is strongly associated with chromosome 13 abnormalities in both multiple myeloma and monoclonal gammopathy of undetermined significance [J].

Fonseca, R ;

Oken, MM ;

Greipp, PR .

BLOOD, 2001, 98 (04) :1271-1272

[14] Chromosome 8q24.1/c-MYC abnormality: a marker for high-risk myeloma [J].

Glitza, Isabella C. ;

Lu, Gary ;

Shah, Rupin ;

Bashir, Qaiser ;

Shah, Nina ;

Champlin, Richard E. ;

Shah, Jatin ;

Orlowski, Robert Z. ;

Qazilbash, Muzaffar H. .

LEUKEMIA & LYMPHOMA, 2015, 56 (03) :602-607

[15] Next Generation Sequencing-based Validation of the Revised International Staging System for Multiple Myeloma: An Analysis of the MMRF CoMMpass Study [J].

Goldsmith, Scott R. ;

Fiala, Mark A. ;

Dukeman, James ;

Ghobadi, Armin ;

Stockerl-Goldstein, Keith ;

Schroeder, Mark A. ;

Tomasson, Michael ;

Wildes, Tanya M. ;

Vij, Ravi .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (05) :285-289

[16] International staging system for multiple myeloma [J].

Greipp, PR ;

San Miguel, J ;

Durie, BGM ;

Crowley, JJ ;

Barlogie, B ;

Bladé, J ;

Boccadoro, M ;

Child, JA ;

Harousseau, JL ;

Kyle, RA ;

Lahuerta, JJ ;

Ludwig, H ;

Morgan, G ;

Powles, R ;

Shimizu, K ;

Shustik, C ;

Sonneveld, P ;

Tosi, P ;

Turesson, I ;

Westin, J .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (15) :3412-3420

[17] REGRESSION MODELING STRATEGIES FOR IMPROVED PROGNOSTIC PREDICTION [J].

HARRELL, FE ;

LEE, KL ;

CALIFF, RM ;

PRYOR, DB ;

ROSATI, RA .

STATISTICS IN MEDICINE, 1984, 3 (02) :143-152

[18] Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients [J].

Hebraud, B. ;

Leleu, X. ;

Lauwers-Cances, V. ;

Roussel, M. ;

Caillot, D. ;

Marit, G. ;

Karlin, L. ;

Hulin, C. ;

Gentil, C. ;

Guilhot, F. ;

Garderet, L. ;

Lamy, T. ;

Brechignac, S. ;

Pegourie, B. ;

Jaubert, J. ;

Dib, M. ;

Stoppa, A-M ;

Sebban, C. ;

Fohrer, C. ;

Fontan, J. ;

Fruchart, C. ;

Macro, M. ;

Orsini-Piocelle, F. ;

Lepeu, G. ;

Sohn, C. ;

Corre, J. ;

Facon, T. ;

Moreau, P. ;

Attal, M. ;

Avet-Loiseau, H. .

LEUKEMIA, 2014, 28 (03) :675-679

[19] NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].

KAPLAN, EL ;

MEIER, P .

JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481

[20] Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma [J].

Kastritis, Efstathios ;

Terpos, Evangelos ;

Roussou, Maria ;

Gavriatopoulou, Maria ;

Migkou, Magdalini ;

Eleutherakis-Papaiakovou, Evangelos ;

Fotiou, Despoina ;

Ziogas, Dimitrios ;

Panagiotidis, Ioannis ;

Kafantari, Eftychia ;

Giannouli, Stavroula ;

Zomas, Athanasios ;

Konstantopoulos, Konstantinos ;

Dimopoulos, Meletios A. .

HAEMATOLOGICA, 2017, 102 (03) :593-599

← 1 2 3 4 →